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INTRODUCTION
For patients with end-stage renal disease (ESRD) 
undergoing hemodialysis, appropriate care of vascular access 
is essential to optimal management (1). The recommended 
order of the type and location of long-term hemodialysis 
access is as follows: 1) via an arteriovenous (AV) fistula, 
rather than a prosthetic AV graft; 2) distal placement; and 
3) in the upper extremities, whenever possible (1). In some 
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cases, when there is a prior history of autogenous AV fistula 
access abandonment with no remaining vessels for creating 
autogenous AV fistulae, or when there is no candidate 
for the creation of a primary AV fistula due to small vein 
diameter (< 2.5 mm), a prosthetic AV graft is recommended.
Frequent thrombosis is a well-known and notorious 
problem in prosthetic AV grafts, and in 1989 the pulsed-
spray pharmacomechanical thrombolysis (PMT) technique 
was introduced for prosthetic AV graft declotting (2). Since 
that time the PMT technique has been widely accepted 
for the treatment of prosthetic AV graft thrombosis, 
although the long procedure time was problematic. Thus, 
several mechanical thrombectomy devices, such as the 
AngioJet rheolytic catheter (AngioJet AVX; Possis Medical, 
Inc., Minneapolis, MN, USA) and the Arrow-Trerotola 
percutaneous thrombolytic device (Arrow International, 
Inc., Reading, PA, USA), have been introduced for the 
treatment of thrombosed prosthetic AV grafts. Despite the 
established effectiveness and safety, the increased costs 
of these devices place a burden on patients, resulting in 
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limited use for patients who have organized thrombi.
Generally, with the traditional PMT technique, a few hours 
are required for infusion and maintenance of the fibrinolytic 
agent within the AV graft, and the total amount of the 
fibrinolytic agent is relatively high (approximately 250,000-
1,000,000 IU of urokinase) (2-7). Therefore, even though 
the traditional PMT technique is the effective method, the 
long procedure time and hemorrhagic complications related 
to the amount of fibrinolytic agent are major concerns. 
We propose that the infusion of a lower dose of urokinase 
through the AV graft within a shorter time without the 
use of special devices, such as mechanical thrombectomy 
devices or multiside-hole infusion catheters, will reduce 
the procedure time, improve the clinical outcomes, and 
decrease concerns about hemorrhagic complications, all 
without incurring additional medical expenses. We applied a 
modified PMT technique for thrombosed prosthetic AV grafts 
without the use of special devices, such as mechanical 
thrombectomy devices or multiside-hole infusion catheters. 
The aim of this study was to evaluate the efficacy of the 
modified PMT technique in the endovascular treatment 
of thrombosed prosthetic AV grafts by analyzing post-
intervention primary and secondary patencies, and to 
identify the prognostic factors affecting the outcome.
MATERIALS AND METHODS
Patients
Between March 2005 and October 2009, 761 cases 
with hemodialysis vascular access in 344 patients were 
referred from our hospital hemodialysis center and satellite 
hemodialysis clinics for diagnostic fistulography and/or 
endovascular treatment. The cases included 548 cases (72%) 
of prosthetic AV grafts in 169 patients and 213 cases (28%) 
of AV fistulas in 175 patients. Among the 169 patients 
with a prosthetic AV grafts, 82 patients (M:F = 42:40; age, 
59.6 ± 12.8 years; age range, 29-85 years) with prosthetic 
AV grafts presented with complete graft occlusion with 
thrombosis and were treated with the modified PMT 
technique, followed by angioplasty of the stenotic lesion 
using a balloon catheter. The material used in all of the 
prosthetic AV grafts was expanded polytetrafluoroethylene. 
The other 87 patients presented with a draining vein and/or 
central vein stenosis with preserved graft patency.
If a decreased or absent thrill was noted on the physical 
examination through the AV graft, the patient was referred 
for diagnostic fistulography and endovascular therapy. 
Exclusion criteria for endovascular treatment of AV graft 
in our angiography suite were as follows: 1) recent AV 
graft placement or surgical revision (< 2 weeks); 2) the 
presence of a risk factor for bleeding from anticoagulation 
or fibrinolytic therapy; 3) a suspected AV graft infection; or 
4) a severe contrast allergy.
Inclusion criteria of the study were as follows: 1) 
prosthetic AV graft occlusion with thrombosis; and 2) 
endovascular treatment was attempted for the AV graft 
salvage. Exclusion criteria were as follows: 1) AV graft 
occlusion occurring over 48 hours; and 2) a history of 
endovascular treatment for AV graft salvage performed at 
outside hospitals. 
Table 1. Clinical Characteristics of 82 Patients with Prosthetic Arteriovenous Grafts
Characteristics Value
Age, mean ± standard deviation 59.6 ± 12.8 years
Age range 29-85 years
Gender (male:female) 42:40
History of previous graft/fistula, n (%) 49 (60)
Graft location and configuration Forearm loop Right, left 5, 51
Upper arm (straight or curved) Right, left 3, 19
Upper arm loop Right, left 1, 2
Thigh Right, left 1, 0
Cause of end-stage renal disease, n (%) Diabetes mellitus 38 (46)
Hypertension 15 (18)
Chronic glomerulonephritis 15 (18)
Other diseases* 14 (17)
Note.— *Other diseases included genetic disease (n = 2), obstructive nephropathy (n = 5), unknown cause (n = 5), drug-induced 
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Table 1 shows the patient characteristics of the study 
group. Before the procedure was performed, written 
informed consent was obtained from all the patients. 
Institutional Review Board approval was obtained for this 
study.
Collection of Information
We retrospectively reviewed hospital medical records, 
hemodialysis unit records, angiography suite records, 
and surgical records of the 82 patients in relation to the 
hemodialysis and endovascular treatments. 
Techniques
All procedures were performed percutaneously in 
angiography suites by two interventional radiologists 
with nine and 12 years of experience. The modified PMT 
technique included the following steps:
1) Pre-procedural examination. A physical examination 
was performed through the entire prosthetic AV graft.
2) Venous access. After local anesthesia, the AV graft 
was cannulated approximately 3-5 cm from the arterial 
anastomosis with an 18-gauge access needle (Becton 
Dickinson Korea, Ltd., Seoul, Korea) pointing towards the 
venous anastomosis. A 0.035-inch hydrophilic guidewire 
(Terumo, Tokyo, Japan) was then passed up to the central 
vein under fluoroscopy, if possible. Next, a 6-Fr introducer 
sheath (Terumo) was inserted over the guidewire toward the 
central vein following the insertion of a 5-Fr catheter (Cook, 
Bloomington, IN, USA), if possible. An angiogram of the 
draining and central veins was subsequently performed. 
3) Arterial access and thrombolysis. A second AV graft 
cannulation was performed under local anesthesia, 3-5 
cm away from the venous anastomosis using a 5-Fr 
micropuncture introducer set (Cook) directed towards the 
arterial anastomosis. The catheter tip was advanced near the 
arterial anastomosis. After the gentle injection of a small 
amount of diluted contrast material through the 5-Fr coaxial 
outer catheter, including a micropuncture introducer set 
(Cook) to evaluate the arterial anastomosis, while avoiding 
reflux of the thrombus, 200,000 IU of urokinase (Yuhan, 
Seoul, Korea) were dissolved in 5 mL of sterile normal saline 
and the solution was slowly infused over 5 minutes through 
the catheter to start the thrombolysis under manual 
compression of the arterial anastomosis. This was followed 
by gentle manual massage of the AV graft to spread the 
solution through the clot and to intermittently obstruct the 
venous limb to aid the penetration of the arterial limb. No 
additional urokinase infusion was performed. A concomitant 
systemic intravenous injection of 3000 U of heparin 
(heparin sodium injection; Choongwae, Seoul, Korea) was 
performed, as needed, to maintain an activated clotting 
time > 200 seconds. The urokinase solution was left in 
situ for approximately 20 minutes. Next, the 5-Fr coaxial 
outer catheter (Cook) was exchanged for a 0.035-inch 
guidewire, and the venous anastomosis site stenosis and/or 
central venous stenosis were dilated using a non-compliant 
balloon catheter (Blue Max; Boston Scientific, Natick, MA, 
USA) with a 60-second balloon inflation time. The detailed 
angioplasty technique was previously described (4). Balloon 
maceration of the thrombus was subsequently performed 
first via venous access, and a 6-Fr vascular sheath (Terumo) 
was then inserted toward the arterial anastomosis, followed 
by balloon maceration. Balloon maceration was performed 
through the entire AV graft using an over-the-wire non-
compliant balloon catheter (Blue Max) or a semi-compliant 
balloon catheter (Power Flex; Cordis, Bridgewater, NJ, USA) 
inflated with 50% contrast solution under fluoroscopy. With 
respect to the arterial plug, a partially inflated angioplasty 
balloon was used and gently pulled back through the 
arterial anastomosis. Then, an angiogram was performed. 
If a large residual thrombus remained within the AV graft, 
repeat balloon dilatation was performed to dislodge 
the thrombus and re-establish flow. Brisk injection of a 
burst of saline into the AV graft was occasionally used to 
dislodge the thrombus and re-establish flow. During this 
thrombolysis procedure, the vascular sheath, which was 
within the arterial segment, could be temporarily removed 
over a guidewire to facilitate thrombus removal.
The balloon diameter was chosen at the operator’s 
discretion, generally starting with a balloon 1 mm larger 
in diameter than the AV graft and/or the patient’s previous 
fistulography or angioplasty report, if available.
Regarding the loop AV graft, the apex-puncture technique 
was used for the venous and arterial access processes using 
5-Fr micropuncture introducer sets (Cook) (8). The arterial 
and venous access and thrombolysis procedures were 
performed in the same manner with the above maneuver. 
In case of clinically significant apical stenosis or thrombus 
behind the sheath, an additional puncture was performed 
at the venous limb, followed by PTA or balloon maceration, 
respectively.
4) Angioplasty. Angioplasty of the stenotic lesions 
(arterial anastomosis, AV graft venous outflow, and 
draining or central veins) was performed using a balloon Korean J Radiol 13(3), May/Jun 2012 kjronline.org 303
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catheter (Boston Scientific or Cordis). The balloon size was 
determined using a 10-20% oversized balloon, compared 
with an adjacent normal vein, proximal to the stenosis, 
and/or the patient’s previous fistulography or angioplasty 
report, if available.
The angioplasty balloon was inflated gradually until the 
stenosis was eliminated, then the inflation pressure of the 
balloon was maintained for 60 seconds. If the waist of the 
stenosis was not eliminated after maximal inflation pressure 
for 60 seconds, either a cutting balloon (Peripheral Cutting 
Balloon; Boston Scientific) or a non-compliant high-
pressure balloon (Conquest Balloon; Bard, Inc., Covington, 
GA, USA) was used to eliminate the stenosis (9, 10). If 
significant residual stenosis was again noted, stenting was 
performed using a self-expandable nitinol stent (Zilver; 
Cook or Smart Control; Cordis).
5) Completion angiogram. After a good clinical thrill was 
detected, a diagnostic angiogram was performed from the 
arterial anastomosis to the central vein. 
6) Hemostasis. The sheath was removed, immediately 
followed by a circular suture around the cutaneous incision, 
and additional manual compression, if needed, was 
performed until hemostasis was achieved (11). The puncture 
sites were covered with Band-Aid adhesive bandages 
(Johnson & Johnson Medical Korea, Seoul, Korea).
After successful thrombolysis, the AV graft was 
immediately used for hemodialysis. No prophylactic 
antibiotics were used in relation to the procedure. In the 
case of stenting, anti-platelet treatment was recommended.
Follow Up
All patients were followed up at the hemodialysis units. 
Follow-up examinations were the same as those used in 
the surveillance protocol. Patients with abnormal clinical 
parameters suggestive of AV graft dysfunction, including 
persistent swelling of the arm, presence of collateral veins, 
prolonged bleeding after needle withdrawal, or altered 
characteristics of pulses or thrills in grafts, were referred 
for repeated fistulography and endovascular treatment. In 
addition, static pressure in the graft of each patient was 
directly measured at least monthly using transducers on 
hemodialysis machines. Therefore, patients with an AV graft 
exhibiting a venous segment static pressure ratio > 0.5 or 
an arterial segment static pressure ratio > 0.75 were also 
referred. 
Study Outcome and Definition
The reporting standards from the Committee on Reporting 
Standards of the Society for Vascular Surgery and the 
American Association for Vascular Surgery were used to 
define the AV graft patency (12-14).
Technical success was considered the presence of a 
patent AV graft at the conclusion of the procedure, as a 
reduction of the stenosis to < 30% of the luminal diameter 
on angiogram, based on a good thrill. Clinical success 
was considered to be at least one successful subsequent 
hemodialysis session (1).
Post-intervention primary patency was defined as the 
interval from the time of intervention until thrombosis 
or until the time of measurement of patency. Secondary 
patency was defined as the interval from the time of access 
placement until any intervention designed to maintain or 
re-establish patency, until access thrombosis, or until the 
time of measurement of patency (12-14). 
Statistical Analyses
Statistical analyses were performed using SPSS for 
Windows (version 16.0; SPSS Inc., Chicago, IL, USA). Access 
patency rates were calculated using the Kaplan-Meier 
method and were compared using the log-rank Mantel-Cox 
test. Independent predictors of patency were calculated 
using Cox regression analysis. A p value < 0.05 was deemed 
to indicate a statistically significant difference.
RESULTS
The total number of modified PMT sessions was 279 
in 82 patients. The mean follow-up period after the first 
interventional treatment was 782.2 days (range, 0-2377 
days). During the follow-up evaluation, 21 patients (26%) 
underwent no additional interventions, and the other 61 
patients (74%) underwent at least one more intervention. 
Two patients (2%) were lost to followup. The modified 
PMT was technically successful in 95% of 82 patients 
with 279 sessions, and clinically successful in 95% of the 
patients with technical success. The post-intervention 
primary patency rates at 3, 6, 12, and 24 months were 80 ± 
4.7%, 56 ± 5.9%, 45 ± 6.0%, and 22 ± 5.4%, respectively. 
The secondary patency rates at 3, 6, 12, and 24 months 
were 100 ± 0.0%, 98 ± 1.7%, 96 ± 2.1%, and 91 ± 3.2%, 
respectively. The Kaplan-Meier survival curves for the overall 
post-intervention primary and secondary patencies of the 
thrombosed AV grafts are shown in Figure 1. The median Korean J Radiol 13(3), May/Jun 2012 kjronline.org 304
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durations of the post-intervention primary and secondary 
patencies were 9.1 ± 3.2 and 97.4 ± 12.7 months, 
respectively.
Age, gender, history of previous vascular access procedure, 
AV graft shape (loops, straight, or curved), and AV graft side 
(right or left) showed no effect on the post-intervention 
primary or secondary patency rates. The post-intervention 
primary patency had no effect on the secondary patency 
rate. There were eight overall stent insertions for the 
treatment of residual venous stenosis.
There were no major complications that required prolonged 
hospitalization with surgical or medical treatment. Among 
all 279 procedures, 29 cases (10%) of minor complications 
occurred. Vein rupture following percutaneous transluminal 
angioplasty was a common complication, occurring in 17 
cases (16%; 13 venous anastomosis sites and 4 draining 
veins) treated with ballooning in 14 cases or with a stent 
in 3 cases). Seven cases (3%) of AV graft extravasation 
occurred and were treated with manual compression. Three 
cases (1%) of arterial embolization occurred and were 
treated with local urokinase infusion. One case (0.4%) of 
arterial rupture occurred and was treated with ballooning, 
while one case (0.4%) of arterial dissection occurred and 
was treated with stent placement. There were no mortalities 
related to the procedure.
DISCUSSION
Thrombosis is the leading cause of AV graft patency 
loss. Thus, timely intervention for a thrombosed access is 
mandatory to re-establish the connection to the artificial 
kidney.
Since the late 1980s, endovascular treatment methods, 
such as PMT and mechanical declotting techniques, have 
been replaced with the AV graft occlusion recanalization 
treatment method, rather than surgical treatment, and have 
been shown to be efficacious and safe (2, 4, 6, 15). As a 
result of technical innovations, several mechanical devices 
were introduced in the early 1990s, and currently several 
commercial mechanical devices are widely used for the 
endovascular treatment of thrombosed AV grafts (16-20). 
Despite the convenience of handling, the short procedure 
time, and the effectiveness and safety of these devices, a 
major drawback associated with the use of these mechanical 
devices is the high cost.
The current study showed that a modified PMT technique, 
coupled with close monitoring and early referral, is a highly 
successful procedure with acceptable long-term secondary 
patency rates. Based on our modified PMT technique, a 
urokinase infusion was performed over a relatively short 
time as the arterial anastomosis site was compressed. This 
modified PMT technique does not require a multiside-hold 
infusion catheter for fibrinolytic agent infusion, making it 
simpler than traditional PMT techniques (3, 4, 6, 21, 22). 
Also, the total amount of urokinase was 200,000 IU, which 
may reduce the risk of hemorrhagic complications related 
to urokinase. In addition, the overall lytic time was 25 
minutes, which was much shorter than the traditional PMT 
technique, and may effectively reduce the overall procedure 
time. Our study outcomes demonstrated the effectiveness 
of the technique, with 95% and 95% technical and clinical 
success rates, respectively. These results are comparable 
with previous reports using mechanical thrombectomy 
devices, which reported rates between 80% and 98% (19, 
23-27). Moreover, our modified PMT technique results 
have acceptable post-interventional primary patency 
and secondary patencies, with low complication rates. 
Furthermore, our post-intervention primary patency 
results far exceeded the recommended target of 40% 
patency at three months, as set by the KDOQI guidelines 
(1). Continuous AV graft surveillance and early referral 
for endovascular treatment could improve the long-term 
patency of AV grafts, and these modalities will contribute 
to improving the quality of life for hemodialysis patients.
Based on our modified PMT technique, urokinase was 
infused into the AV graft under manual compression of 
the arterial anastomosis. However, compared with manual 
Fig. 1. Kaplan-Meier curves of overall post-intervention 
primary and secondary patencies of thrombosed arteriovenous 
grafts. Censored data are indicated by vertical bars at data points.
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compression, the use of a balloon catheter is expected 
to result in more effective occlusion of the arterial 
anastomosis. Although arterial embolization may occur 
during balloon catheter manipulation, an experienced 
operator could achieve more effective occlusion. 
There were some limitations to our study. This was a 
retrospective study confined to patients with acute AV graft 
thrombosis. However, for patients with chronic AV graft 
thrombosis, endovascular treatment using a mechanical 
thrombectomy device is an excellent treatment option. In 
the current study we excluded AV graft occlusion occurring 
over 48 hours previously from the study analysis, but not 
the treatment itself, because thrombus age is a bias for 
analysis of the modified PMT technique. In addition, the 
overall procedure times and relationship between the lytic 
time and overall procedure time remain to be evaluated.
In conclusion, our modified PMT technique for thrombosed 
prosthetic AV grafts is a highly successful procedure 
with acceptable long-term post-intervention primary 
and secondary patencies, provided that an endovascular 
treatment is established to manage subsequent thrombosis.
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